We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Martina
Furegato
mfuregat@sgul.ac.uk
Dr
Tariq
Sadiq
ssadiq@sgul.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
Infections with a predominantly sexual mode of transmission
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Testing for sexually transmitted infections (STIs) enables diagnosis and appropriate clinical management of individuals, thus preventing serious health consequences. It is an important public health intervention with potential to reduce onward transmission of infection to sexual partners, and reducing the emergence of antimicrobial resistance (AMR). New technologies, including point of care tests (POCTs), especially those that combine detection of the pathogen and AMR, may help overcome challenges of STI prevention by enabling immediate diagnosis and appropriate treatment, improving partner notification, quality of patient care and antibiotic stewardship.
Through a three-year NIHR i4i-funded grant (II-LB-0214-20005), the team at St George’s University of London have been working with Atlas Genetics, to develop a POCT for diagnosis and AMR for the two STIs Neisseria gonorrhoeae (NG) and Mycoplasma genitalium (MG). We are now able to conduct a prospective diagnostic accuracy study of the test using patient-consented (additional to routine) clinical samples, to evaluate the Atlas io platforms and its associated cartridges. For NG, the primary outcome is to set the detection level whereby samples are considered negative and assess the test’s utility as a reflex test for patients already diagnosed with NG. For MG, we will look at the accuracy of detection and AMR. Secondary outcomes are an epidemiological description of the recruited population, and modelling clinical impact of POCTs.
We will work with Atlas Genetics and a number of UK NHS Genitourinary Medicine (GUM) clinics, over 12 months. Following informed consent, females will be asked to provide 2 additional vulvo-vaginal swabs, males an additional portion of first void urine, and men-who-have-sex-with men (MSM) two additional pharyngeal and rectal swabs. The results of the tests will not be used to inform patient care. Participants will only be recruited during one routine clinical visit, no follow up is required.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cross-sectional;
You can take part if:
You may not be able to take part if:
Patients that do not meet all of inclusion criteria will not be eligible.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Dr
Tariq
Sadiq
ssadiq@sgul.ac.uk
Martina
Furegato
mfuregat@sgul.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
The study is sponsored by St. George's Hospital Medical School and funded by NIHR Central Commissioning Facility (CCF) .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 33444
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
